Reading UTMD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track UTMD free→Reading UTMD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track UTMD free→QuarterlyIQ Insights · UTMD
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
RESULTS OF OPERATIONS AND FINANCIAL CONDITION Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three months ended March 31, 2026 and forward-looking statements relating to 2026 and beyond as presented in a press release dated April 23, 2026. The information in this report (including Exhibit 99.1) is being furnished pursuant to
RESULTS OF OPERATIONS AND FINANCIAL CONDITION Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three and twelve months ended December 31, 2025 and forward-looking statements relating to 2025 and beyond as presented in a press release dated January 29, 2026. The information in this report (including Exhibit 99.1) is being furnished pursuant to
DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. On October 31, 2025, the Board of Directors of Utah Medical Products, Inc. (UTMD) voted to increase the size of the Board of Directors from five to six members and to appoint Kevin Timken to fill the vacancy created by the increase in the number of directors. Mr. Timken will serve on the Board’s Audit Committee and Compensation and Benefits Committ…
OTHER EVENTS On November 4, 2025, Utah Medical Products, Inc. announced that it is increasing its regular quarterly cash dividend. A dividend of $.31 per share is payable on January 5, 2026 to shareholders of record at the close of business on December 16, 2025. A copy of the press release is attached hereto as Exhibit 99.1.
RESULTS OF OPERATIONS AND FINANCIAL CONDITION Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three and nine months ended September 30, 2025 and forward-looking statements relating to 2025 and beyond as presented in a press release dated October 23, 2025. The information in this report (including Exhibit 99.1) is being furnished pursuant to
RESULTS OF OPERATIONS AND FINANCIAL CONDITION Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three and six months ended June 30, 2025 and forward-looking statements relating to 2025 and beyond as presented in a press release dated July 24, 2025. The information in this report (including Exhibit 99.1) is being furnished pursuant to
RESULTS OF OPERATIONS AND FINANCIAL CONDITION Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three months ended March 31, 2025 and forward-looking statements relating to 2025 and beyond as presented in a press release dated April 29, 2025. The information in this report (including Exhibit 99.1) is being furnished pursuant to
RESULTS OF OPERATIONS AND FINANCIAL CONDITION Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three and twelve months ended December 31, 2024 and forward-looking statements relating to 2024 and beyond as presented in a press release dated January 28, 2025. The information in this report (including Exhibit 99.1) is being furnished pursuant to
Importance-ranked changes since the prior daily snapshot.
Valuation label changed from 'full' to 'fair'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.